JPRN-UMIN000004207招募中2 期
A Phase II Study of Erlotinib monotherapy for patients with non-small cell lung cancer wihtout EGFR mutation - A phase II study of Erlotinib for NSCLC wihtout EGFR mutation
Hokuriku Lung Cancer Study Group0 个研究点目标入组 120 人开始时间: 2010年9月17日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 120
研究概览
简要总结
patients are recruiting
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) severe interstitial lung disease or pulmonary fibrosis. 2) patient with history of drug-related lung disease. 3) Severe drug allrgy. 4) Patients with complication of infectious disease. 5) patients with Severe diarrhea 6) Patients with clinically significant ball disease. 7) patients with clinically significant opthalmologic disorder. 8) patients with complication or hisotry of gastrointestinal perforation. 9) Uncontrolable GI ulcer. 10) Brain metastasis with symptoms 11) Active multiple cancer. 12) patients with clinically significant heart disease. 13) Patients with clinically siginificant psychologic disease. 14) Patients with lactation or pregnancy. 15) patients who are considered ineligible based on decision of a reasonable investigator.
研究者
相似试验
已完成
2 期
Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAdult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2AAdult Acute Promyelocytic Leukemia With PML-RARAAlkylating Agent-Related Acute Myeloid LeukemiaPreviously Treated Myelodysplastic SyndromeRecurrent Adult Acute Myeloid LeukemiaMyelodysplastic SyndromeChronic Myelomonocytic LeukemiaNCT01664897M.D. Anderson Cancer Center29
已完成
2 期
Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or AdenomaAdenomatous PolypRecurrent Colon CancerRecurrent Rectal CancerStage I Colon CancerStage I Rectal CancerStage IIA Colon CancerStage IIA Rectal CancerStage IIB Colon CancerStage IIB Rectal CancerStage IIC Colon CancerStage IIC Rectal CancerStage IIIA Colon CancerStage IIIA Rectal CancerStage IIIB Colon CancerStage IIIB Rectal CancerStage IIIC Colon CancerStage IIIC Rectal CancerNCT00754494National Cancer Institute (NCI)45
终止
2 期
A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast CancerBreast NeoplasmsCancer of the BreastBreast CancerNCT01272141Emory University5
终止
2 期
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric EpendymomaRecurrent or Refractory Pediatric EpendymomaNCT01032070OSI Pharmaceuticals25
进行中（未招募）
2 期
Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.Low-grade GliomaPlexiform NeurofibromaCentral Nervous System GliomaNCT03363217St. Justine's Hospital114